If you have been searching Wegovy RAMQ, you have probably already found the frustrating part. One semaglutide product shows up on the Quebec public plan list and another does not, even though the active ingredient is the same molecule. That is not a website error. It is how drug formularies work, and understanding it changes what you do next.
Key takeaways
- A search of RAMQ’s covered-drug tool for semaglutide returns the injectable brand, the oral tablet form, and two authorized generic injectables, all marked as exception medications.
- Products authorized specifically for chronic weight management, including this one, do not return a result in that same search tool.
- A drug that is absent from the list is in a different position from one listed with conditions. There is no exception request to submit for a product that is not listed.
- Quebec requires every resident to hold drug insurance. If you have access to a private plan, you are required to be in it, and that plan’s own rules apply.
- Private plans in Quebec set their own formularies. Some cover this category with prior authorization, some exclude it entirely.
- Formulary lists are revised on a published schedule, so status is a snapshot rather than a permanent state.
Why two products with the same active ingredient are treated differently
This is the part that makes people assume something has gone wrong.
Semaglutide is one molecule. In Canada it is sold under more than one authorized product, at different dose ranges, for different authorized uses. A drug plan does not make one decision about a molecule. It makes a separate decision about each authorized product, tied to the use it was authorized for.
So a formulary never answers the question of whether it covers semaglutide. It answers a narrower one. Does it cover this specific product, at this dose range, for this authorized use, and on what conditions.
Once you see it that way, the split stops looking arbitrary. Public drug plans across Canada have generally been slower to list products authorized for chronic weight management than products authorized for glycemic control in type 2 diabetes. Quebec is not unusual in this. The pattern reflects how payers have historically assessed the two use cases, not a judgment about whether the molecule works.
Wegovy RAMQ: what the public plan list shows
RAMQ publishes a List of Medications and a public search tool. Anyone can check a drug or an active ingredient and see its status without logging in.
As of the verification date at the end of this article, searching that tool for semaglutide returns four products. All four carry the exception medication label, which means coverage requires the prescriber to submit a request and RAMQ to authorize it against a recognized payment indication.
Running the search for products authorized specifically for chronic weight management returns nothing.
That distinction is worth sitting with, because people conflate the two constantly:
| Situation | What it means for you |
|---|---|
| Listed as a regular medication | Covered when a valid prescription is filled |
| Listed as an exception medication | Covered only if your prescriber requests authorization and RAMQ grants it for a recognized indication |
| Not on the list at all | No public plan coverage and no exception pathway to request |
If a product is not on the list, asking your prescriber to submit an exception request will not help. There is nothing to request against. That is a hard thing to read, and it is better than spending three weeks finding it out one phone call at a time.
What private plans in Quebec actually do
Here is where the answer stops being a single answer.
Quebec is the only province where drug insurance is compulsory. Under the Act respecting prescription drug insurance, access to a private plan changes your obligations. If one is available through an employer, a union, or a professional order, you are required to be covered by it rather than by the public plan. Most working adults in Quebec are therefore in a private plan, not in the RAMQ public plan at all.
Private plans set their own formularies. In this category they vary more than in almost any other:
- Some cover products authorized for chronic weight management with prior authorization, typically requiring documented clinical criteria
- Some cover them with an annual or lifetime maximum
- Some exclude the category entirely as a plan design choice
- Some cover one product and not another, mirroring the public split
The only reliable source is your own plan. Your benefits booklet will have a section on prior authorization and on excluded categories. If the booklet is ambiguous, the insurer’s member line can confirm whether a specific drug identification number is eligible under your plan.
That call is worth making before you assume the answer. A meaningful share of people who assume they have no coverage do have coverage subject to a prior authorization form they have never been told about.
If you have no coverage
Some people will finish that call with a clear no. It is worth being straightforward about what that leaves.
The category is broader than one product. More than one authorized product exists in the GLP-1 receptor agonist class in Canada, in both injectable and oral formats, at different dose ranges. Authorized generic semaglutide injectables from more than one Canadian manufacturer are now listed by RAMQ alongside the brand. A provider can talk through which formats are clinically appropriate for you, and cost differences between them are real.
Compounded preparations are a distinct category with distinct considerations. They are not authorized products, and the appropriate way to think about them is a clinical conversation rather than a price comparison. A licensed provider and pharmacist should be the ones explaining the difference.
Treatment is not only pharmacological. Structured nutrition and activity support, and management of contributing conditions, are part of medically supervised weight management regardless of whether a medication is involved.
A provider can talk you through the formats. Our weight management article library covers what each option involves before cost enters the conversation.
Status is not permanent. RAMQ revises its list on a published schedule. Private plans renew annually and formularies change at renewal. A no this year is not necessarily a no next year.
If you want the full picture of what exists in Canada rather than one product’s coverage status, our complete guide to GLP-1 options in Canada covers the authorized products and how the formats differ.
What could change
Two things are worth watching, stated plainly and without prediction.
Authorized generic semaglutide injectables have entered the Canadian market and now appear on the RAMQ list. Generic entry generally changes acquisition costs, and payers reassess listings when it does.
Provincial formulary lists are revised on published schedules. RAMQ publishes its update calendar, and changes take effect on defined dates rather than quietly.
Neither of those is a reason to wait. They are a reason to check the current status yourself rather than relying on an article, including this one.
Been told you are not covered, and not sure what is left? That is exactly the conversation MyRocky exists for. A licensed Canadian prescriber can talk you through which options are clinically appropriate for you, including formats and authorized generics you may not have been offered, rather than leaving you to work it out from a denial letter. Start with the online assessment and go from there.
Safety and who should speak to a healthcare provider first
GLP-1 receptor agonists are prescription medications and are not appropriate for everyone. The decision to start, continue, or stop one belongs with a licensed healthcare provider who has your history.
Speak with a provider before considering this class of medication if any of the following apply:
- A personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2
- A history of pancreatitis
- Active gallbladder disease
- Pregnancy, planned pregnancy, or breastfeeding
- Severe gastrointestinal disease, including gastroparesis
- Type 1 diabetes
- Current use of other glucose-lowering medication
Gastrointestinal effects are the most commonly reported with this class, including nausea, vomiting, diarrhea and constipation. Less common but serious adverse effects are documented in the Canadian product monographs, and a provider should review them with you before you start.
Cost pressure is not a clinical reason to change a dose, stretch a prescription, or source a medication outside a licensed pharmacy. If affordability is the obstacle, that is a conversation to have with your provider directly.
Frequently asked questions
Is Wegovy covered by RAMQ?
Products authorized specifically for chronic weight management do not return a result in RAMQ’s covered-drug search tool. That means no public plan coverage and no exception request pathway, which is different from being listed with conditions. Confirm current status in RAMQ’s tool before acting.
Why does RAMQ list one semaglutide product and not another?
Formularies make decisions about specific authorized products tied to specific authorized uses, not about active ingredients in general. Public plans across Canada have generally listed products authorized for glycemic control earlier than those authorized for chronic weight management.
Can my doctor submit an exception request for it?
Exception requests are submitted against recognized payment indications for drugs that appear on the list. If a product is not listed at all, there is no indication to request against.
Will my private insurance in Quebec cover it?
That depends entirely on your plan. Quebec private plans vary widely in this category, from prior authorization to full exclusion. Check your benefits booklet and confirm with your insurer using the drug identification number.
How much is Wegovy in Quebec without coverage?
Without coverage you pay the pharmacy’s price, which varies by pharmacy and by dose. Prices are not published by RAMQ because the product is not on the public plan list. Ask your pharmacy directly.
The bottom line
The active ingredient is the same. The formulary position is not, and in Quebec that distinction decides whether you pay a capped contribution or the full pharmacy price.
Two calls are worth more than another hour of searching: one to your insurer to find out what your plan actually says, and one conversation with a provider about which options are clinically appropriate for you.
To work out what fits your situation, see MyRocky’s weight management treatment options or read our complete guide to GLP-1 options in Canada. You can also start an online assessment with a licensed Canadian prescriber.
Coverage status verified against the RAMQ covered-drug search tool and published rate schedule on 30 September 2026. RAMQ revises its List of Medications on a regular schedule. Confirm current status before acting on anything in this article.
References
- Régie de l’assurance maladie du Québec. Find out whether a drug is covered. RAMQ, 2026. https://www.ramq.gouv.qc.ca/en/citizens/prescription-drug-insurance/find-out-whether-a-drug-covered
- Régie de l’assurance maladie du Québec. Rates in effect, 1 July 2026 to 30 June 2027. RAMQ, 2026. https://www.ramq.gouv.qc.ca/en/citizens/prescription-drug-insurance/rates-effect
- Régie de l’assurance maladie du Québec. List of medications. RAMQ, 2026. https://www.ramq.gouv.qc.ca/en/about-us/list-medications
Disclaimer: This article is intended for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider with any questions about a medical condition or treatment.
Editorial Standards: At Rocky Health, we’ve made it our mission to support men and women with trustworthy, easy-to-understand medical and health information online. Read more about our editorial standards here.
